Aromics Biotech

@aromicsbiotech is developing an innovative treatment for mesothelioma, an incurable cancer related to #asbestos exposure. Check it out the advances at @bermesproject, an #H2020 #smeinstrument project funded by @EU_Commission @CORDIS_EU @ComisionEuropea @ComissioEuropea #EWAC2020

Mesocare.org Announces Launch of WikiMesothelioma.com to Expand Public Access to Mesothelioma Information tmcnet.com/usubmit/2026/0…

Catalunya inyectará más de 100 millones para reformar escuelas antiguas, climatizar y retirar amianto elperiodico.com/es/sociedad/20… a través de @elperiodico

El Supremo confirma que un extrabajador del metro de Barcelona sufre una incapacidad total por el amianto laopiniondemurcia.es/sociedad/2026/…

GSK pays $17.5M for CAMP4 regulatory RNA deal fiercebiotech.com/biotech/gsk-pa…

In an oral presentation at the #MDAconference 2025 next week, we will present preclinical data for our lead, rationally designed, RNA-targeted small molecule drug program for treatment of myotonic dystrophy type 1 (DM1). #ExpeditionRNA arrakistx.com/press-release/…

@AVDB2171 they were also among the first....

Skyhawk isn't alone in the RNA space. Arrakis and Remix pursue similar approaches. RNA therapeutics gain momentum after recent approvals. But Skyhawk's 5 pharma partnerships suggest they've proven something others haven't:

Merck KGaA just placed a $2B bet in neuroscience. Not on a blockbuster. Not on a late-stage drug. But on a technology that could unlock diseases once thought “undruggable.” Here’s why pharma boardrooms are paying attention:

📢 Huntington disease drug update New results from Skyhawk Therapeutics’ phase 1 trial show: ✅ SKY-0515 reduced mutant huntingtin (mHTT) by 62% at the high dose ✅ Dose-dependent response in early HD 🧠 A potential step forward in targeting the root cause of HD More data coming mid-2026. 🧪 Read the latest: hubs.li/Q03KlGK_0

Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25 ➡️bit.ly/48u70iy

Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M ACC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Full PR here: bit.ly/4ozZes8

RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence finance.yahoo.com/news/rna-based…

3cat.cat/3catinfo/estud… @CristinaPenyaG @aromicsbiotech

La firma de capital riesgo Asabys absorbe el fondo Alta Life Sciences para ganar músculo inversor en salud y ciencia en España elperiodico.com/es/economia/20… a través de @elperiodico

Impulsando la ley para erradicar el #amianto en Catalunya. Con @FAVBcn, jubilados de Macosa-Alstom y el Dr. Tarrés en el @parlamentcat. #Asbestos #SalutPública #JustíciaAmbiental @bermesproject @aromicsbiotech @CDTI_innovacion @P_Recuperacion

Check out this article: Alarma vecinal por las obras de retirada de amianto en un almacén municipal en Retiro - gacetinmadrid.com/2025/07/07/ala…

Las mujeres alzan su voz contra el talco de los cosméticos por el amianto elpais.com/economia/negoc… a través de @el_pais

El mesotelioma, cáncer raro causado por el amianto, no desciende pese a la prohibición del material elperiodico.com/es/sanidad/202… a través de @elperiodico

Healing Lyme Summit 2.0. On Day 1, April 15, Dr. Horowitz will screen a new documentary featuring 9 chronic Lyme patients who have healed using his dapsone protocol. Also on Day 1 is @lymepolicywonk discussing the findings from MyLymeData. REGISTER NOW: drtalks.com/summit/lyme-su…

La compañía con sede en Badalona (BCN) planea su salto al BME Scaleup, cuenta Rut Font @aromicsbiotech prepara una ronda de 10 millones como antesala de la Bolsa expansion.com/catalunya/2025… a través de @expansioncom

La oportunidad de eliminar todo el amianto que todavía hay en el Maresme via: @Capgros capgros.com/es/maresme/opo…